• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DRONABINOL Drug Record

  • Summary
  • Interactions
  • Claims
  • DRONABINOL chembl:CHEMBL465 Approved

    Alternate Names:

    ABBOTT-40566
    SP-104
    NSC-134454
    DELTA-9-THC
    DRONABINOL
    MARINOL
    J882F
    SYNDROS
    QCD-84924
    DELTA-9-TETRAHYDROCANNABINOL
    QCD 84924
    ABBOTT 40566
    SP 104
    Δ9-THC
    1-TRANS-DELTA-9-TETRAHYDROCANNABINOL
    DELTA9-THC
    3-PENTYL-6,6,9-TRIMETHYL-6A,7,8,10A-TETRAHYDRO-6H-DIBENZO(B,D)PYRAN-1-OL
    (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL
    DELTA(1)-TETRAHYDROCANNABINOL
    DRONABINOLUM
    DRONABINOLEN
    6,6,9-TRIMETHYL-3-PENTYL-6A,7,8,10A-TETRAHYDRO-6H-BENZO[C]CHROMEN-1-OL
    MARINOL®
    THC
    6H-DIBENZO(B,D)PYRAN-1-OL, 6A,7,8,10A-TETRAHYDRO-6,6,9-TRIMETHYL-3-PENTYL-, (6AR,10AR)-
    DELTA(9)-THC
    DELTA9-TETRAHYDROCANNABINOL
    Δ9-TETRAHYDROCANNABINOL
    drugbank:00470
    rxcui:10402
    chemidplus:1972-08-3
    pubchem.compound:16078
    chembl:CHEMBL465

    Drug Info:

    FDA Approval approved
    Drug Class plant extract
    Drug Indications analgesic,neuropathic pain,for treatment of restlegs legs syndrome
    Drug Indications appetite stimulant
    Drug Class Small molecule
    Drug Indications analgesic
    (4 More Sources)

    Publications:

    Suárez et al., 2000, Neuronal and astroglial response to pre- and perinatal exposure to delta-9-tetra- hydrocannabinol in the rat substantia nigra., Dev. Neurosci.
    Burstein et al., 1994, Phospholipase participation in cannabinoid-induced release of free arachidonic acid., Biochem. Pharmacol.
    Davis et al., 2007, The emerging role of cannabinoid neuromodulators in symptom management., Support Care Cancer
    Pertwee, 2009, Emerging strategies for exploiting cannabinoid receptor agonists as medicines., Br. J. Pharmacol.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Pryce et al., 2003, Mifepristone or inhibition of 11beta-hydroxylase activity potentiates the sedating effects of the cannabinoid receptor-1 agonist Delta(9)-tetrahydrocannabinol in mice., Neurosci. Lett.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Tsai et al., 2000, Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia., Psychiatr. Genet.
    Gorriti et al., 2005, Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion., Pharmacol. Biochem. Behav.
    Schuel, 2006, Tuning the oviduct to the anandamide tone., J. Clin. Invest.
    Zhu et al., 2006, Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana., J. Pharmacol. Exp. Ther.
    Butovsky et al., 2005, In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol., J. Neurochem.
  • DRONABINOL   PLA2G2A

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7945419


    Sources:
    NCI

  • DRONABINOL   CNR1

    Interaction Score: 2.17

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name Sativex
    Novel drug target Established target
    Mechanism of Interaction Cannabinoid CB1 receptor agonist

    PMIDs:
    11752352 12686391 17016423 17139284 11204352 15894066


    Sources:
    TdgClinicalTrial ChemblInteractions NCI

  • DRONABINOL   CNR2

    Interaction Score: 1.29

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name CAT-310,Relivar
    Novel drug target Established target
    Trial Name Sativex

    PMIDs:
    17139494 19226257


    Sources:
    TdgClinicalTrial

  • DRONABINOL   FAAH

    Interaction Score: 0.74

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16886056


    Sources:
    NCI

  • DRONABINOL   GFAP

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10965147


    Sources:
    NCI

  • DRONABINOL   BDNF

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15857384


    Sources:
    NCI

  • DRONABINOL   ABCB1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16439618


    Sources:
    NCI

  • DRONABINOL   CYP2C9

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • TdgClinicalTrial: DRONABINOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • TdgClinicalTrial: TETRAHYDROCANNABINOL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications analgesic,neuropathic pain,for treatment of restlegs legs syndrome
    Drug Class plant extract
    FDA Approval approved

    Publications:

  • NCI: TETRAHYDROCANNABINOL

    • Version: 14-September-2017

    Alternate Names:
    C867 NCI drug code

    Drug Info:

    Publications:
    Butovsky et al., 2005, In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol., J. Neurochem.
    Gorriti et al., 2005, Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion., Pharmacol. Biochem. Behav.
    Schuel, 2006, Tuning the oviduct to the anandamide tone., J. Clin. Invest.

  • NCI: THC

    • Version: 14-September-2017

    Alternate Names:
    C867 NCI drug code

    Drug Info:

    Publications:
    Suárez et al., 2000, Neuronal and astroglial response to pre- and perinatal exposure to delta-9-tetra- hydrocannabinol in the rat substantia nigra., Dev. Neurosci.
    Burstein et al., 1994, Phospholipase participation in cannabinoid-induced release of free arachidonic acid., Biochem. Pharmacol.
    Zhu et al., 2006, Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana., J. Pharmacol. Exp. Ther.

  • ChemblDrugs: chembl:CHEMBL465

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL465

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: dronabinol

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Dronabinol

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21